
Healthcare cyber summer sizzle
As summer temperatures reach records, so do HHS and FTC cyber enforcement initiatives.
The Federal Trade Commission (FTC), which is tasked with protecting consumers continued its data privacy and security enforcement streak in June – this time, with an added twist – the first case to focus on genetic information. On
- Leaving sensitive genetic and health data unsecured,
- Deceived consumers about their ability to get their data deleted, and
- Retroactively changed its privacy policy without either adequately notifying or obtaining consumer consent when the company had already collected the data.
The key take-aways from the proposed settlement and FTC press announcement include notable items that compliance officers, executive teams and boards should heed:
- According to Samuel Levine, Director of the FTC’s Bureau of Consumer Protection, “[c]ompanies that try to change the rules of the game by re-writing their privacy policy are on notice [because] [t]he FTC Act prohibits companies from unilaterally applying material privacy policy changes to previously collected data.”
- Strengthen genetic information protections.
- Instruct third-party contract laboratories to destroy all consumer DNA samples that have been retained for more than 180 days.
In sum, companies that handle individually identifiable health information (IIHI) should ensure that they are adhering to HIPAA and NIST technical, administrative, and physical safeguards to protect the security of the consumer’s data, while making sure privacy remains intact by ensuring that the confidentiality and disclosure of such data is not being touted as being compliant when it is not and not getting the appropriate authorizations and consent. Cultivating a culture of compliance is critical and the use of IIHI for remunerative purposes and/or wrongful disclosure is on the FTC’s radar.
Similarly, 
In closing, in order to mitigate liability, even though the FTC Act does not expressly mention compliance with the HIPAA Privacy Rule and the Security Rule or the Genetic Information Non-Disclosure Act (GINA), companies should consider utilizing the resources available on the HHS website to cultivate a culture of compliance and mitigate liability in the long run.
Rachel V. Rose, JD, MBA, advises clients on compliance, transactions, government administrative actions, and litigation involving healthcare, cybersecurity, corporate and securities law, as well as False Claims Act and Dodd-Frank whistleblower cases.
Newsletter
Optimize your practice with the Physicians Practice newsletter, offering management pearls, leadership tips, and business strategies tailored for practice administrators and physicians of any specialty.














